Literature DB >> 10496062

Extended resection for lung cancer invading mediastinal organs.

T Takahashi1, S Akamine, M Morinaga, T Oka, Y Tagawa, H Ayabe.   

Abstract

We analyzed 49 patients with non-small-cell lung cancer invading mediastinal organs such as the left atrium (15), superior vena cava (13), trachea (11), aorta (5), thoracic vertebral body (4) and esophagus (1). Lung resection included lobectomy (37), pneumonectomy (8) and limited resection (4). Twenty-seven patients underwent carina- or bronchoplasty. Complete resection was possible in 35 patients. Operative mortality was 12% and overall 5-year survival was 13%. Median survival time was 519 days. Factors significantly affecting survival were the completeness of resection, node status, and histological type. Five-year survival was 18% with complete resection and 0% with incomplete resection (p < 0.0001). Five-year survival for patients with squamous cell carcinoma was 36% and for those with other types of lung cancer, 0% (p < 0.02). Five-year survival for patients classified pathologically as N0 or N1 was 36% and, for those classified as N2 or N3, 0% (p < 0.05). We concluded that aggressive resection for lung cancer invading the mediastinal organs involves a high mortality rate, making selectivity important. Patients undergoing complete resection, classified as N0 or N1, and having squamouse cell carcinoma may benefit most from surgery.

Entities:  

Mesh:

Year:  1999        PMID: 10496062     DOI: 10.1007/BF03218030

Source DB:  PubMed          Journal:  Jpn J Thorac Cardiovasc Surg        ISSN: 1344-4964


  18 in total

1.  Resection of the superior vena cava for primary lung cancer: 5 years' survival.

Authors:  H Inoue; A Shohtsu; S Koide; J Ogawa; H Inoue
Journal:  Ann Thorac Surg       Date:  1990-10       Impact factor: 4.330

2.  Results of surgical treatment in patients with stage IIIB non-small-cell lung cancer.

Authors:  Y Watanabe; J Shimizu; M Oda; Y Hayashi; Y Tatsuzawa; S Watanabe; H Urayama; T Iwa
Journal:  Thorac Cardiovasc Surg       Date:  1991-02       Impact factor: 1.827

3.  Extended operation for lung cancer invading the aortic arch and superior vena cava.

Authors:  K Nakahara; K Ohno; A Mastumura; H Hirose; H Mastuda; S Nakano; R Shirakura; Y Kawashima
Journal:  J Thorac Cardiovasc Surg       Date:  1989-03       Impact factor: 5.209

Review 4.  A new international staging system for lung cancer.

Authors:  C F Mountain
Journal:  Chest       Date:  1986-04       Impact factor: 9.410

5.  Prospective evaluation of computed tomography and mediastinoscopy in mediastinal lymph node staging.

Authors:  A Gdeedo; P Van Schil; B Corthouts; F Van Mieghem; J Van Meerbeeck; E Van Marck
Journal:  Eur Respir J       Date:  1997-07       Impact factor: 16.671

6.  Extended operation for non-small cell lung cancer invading great vessels and left atrium.

Authors:  T Fukuse; H Wada; S Hitomi
Journal:  Eur J Cardiothorac Surg       Date:  1997-04       Impact factor: 4.191

7.  Management of tumor adherent to the vertebral column.

Authors:  T R DeMeester; M Albertucci; P J Dawson; S M Montner
Journal:  J Thorac Cardiovasc Surg       Date:  1989-03       Impact factor: 5.209

8.  Extended operation for lung cancer invading the superior vena cava.

Authors:  P Thomas; P E Magnan; G Moulin; R Giudicelli; P Fuentes
Journal:  Eur J Cardiothorac Surg       Date:  1994       Impact factor: 4.191

9.  Extended resection of the left atrium, great vessels, or both for lung cancer.

Authors:  R Tsuchiya; H Asamura; H Kondo; T Goya; T Naruke
Journal:  Ann Thorac Surg       Date:  1994-04       Impact factor: 4.330

Review 10.  Multimodality therapy in stage III non-small cell lung cancer.

Authors:  M J Edelman; D R Gandara; M Roach; J R Benfield
Journal:  Ann Thorac Surg       Date:  1996-05       Impact factor: 4.330

View more
  1 in total

Review 1.  Atrial resection for T4 non-small cell lung cancer with left atrium involvement: a systematic review and meta-analysis of survival.

Authors:  Shadi Hamouri; Nasr Alrabadi; Sebawe Syaj; Hassan Abushukair; Obada Ababneh; Leen Al-Kraimeen; Majd Al-Sous; Erich Hecker
Journal:  Surg Today       Date:  2022-01-09       Impact factor: 2.549

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.